Finding room for Recentin

Even though Recentin cediranib from AstraZeneca plc did not achieve non-inferiority to Avastin bevacizumab in the Phase II/III HORIZON III trial, the pharma is hopeful that a place exists for the compound in the metastatic colorectal cancer armamentarium based on its ease of use and ability to block lymphogenesis.

But until it analyzes the full dataset and completes a second Phase II/III trial, HORIZON II, AstraZeneca won't know where Recentin might fit in the treatment paradigm...